NEW YORK (GenomeWeb News) – A clinical study targeting dysferlinopathy expected to cost $3 million has exceeded its patient recruitment goal, the Jain Foundation, which is funding the study, said today.

The Clinical Outcome Study for Dysferlinopathy has recruited 193 patients, passing the original goal of 150. The three-year project is being conducted in 14 centers and is led by Kate Bushby at Newcastle University and Laura Rufibach at the Jain Foundation.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: mitochondrial and nuclear gene fusions in cancer, role of genomic imprinting in tissue-specific gene expression, and more.

Maria Freire from the Foundation for the NIH calls for "politically popular pledges of support" for the NIH to turn into support for increased funding for the agency.

A Thomson Reuters analysis indicates that the life sciences, rather than the tech sector, are increasingly driving global innovation.

The White House says ethical discussions about genome editing of the human germline are needed.